Portal vein embolization with n-butyl-cyanoacrylate through an ipsilateral approach before major hepatectomy: single center analysis of 50 consecutive patients

Cancer Imaging. 2017 Sep 20;17(1):25. doi: 10.1186/s40644-017-0127-3.

Abstract

Purpose: To evaluate the efficacy of portal vein embolization (PVE) with n-Butyl-cyanoacrylate (NBCA) through an ipsilateral approach before major hepatectomy. Secondary end-points were PVE safety, liver resection and patient outcome.

Methods: Over a 5-year period 50 non-cirrhotic consecutive patients were included with primary or secondary liver cancer treatable by hepatectomy with a liver remnant (FLR) volume less than 25% or less than 40% in diseased livers.

Results: There were 37 men and 13 women with a mean age of 57 years. Colorectal liver metastases were the most frequent tumor and patients were previously exposed to chemotherapy. FLR increased from 422 ml to 629 ml (P < 0.001) after PVE, corresponding to anincrease of 52%. The FLR ratio increased from 29.6% to 42.3% (P < 0.001). Kinetic growth rate was 2.98%/week. A negative association was observed between increase in the FLR and FLR ratio and FLR volume before PVE (P = 0.002). In 31 patients hepatectomy was accomplished and only one patient presented with liver insufficiency within 30 days after surgery.

Conclusions: PVE with NBCA through an ipsilateral puncture is effective before major hepatectomy. Meticulous attention is needed especially near the end of the embolization procedure to avoid complications.

Trial registration: Clinical Study ISRCTN registration number: ISRCTN39855523 . Registered March 13th 2017.

Keywords: Embolization; Extended hepatectomy; Future liver remnant; Hepatic insufficiency; Portal vein.

MeSH terms

  • Adult
  • Aged
  • Combined Modality Therapy
  • Embolization, Therapeutic / methods*
  • Enbucrilate / administration & dosage*
  • Female
  • Hepatectomy / methods*
  • Humans
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Portal Vein*
  • Treatment Outcome

Substances

  • Enbucrilate